Report: Houston earns top-10 rank among best U.S. cities for workers making $100K

the good life

Six-figure earners live well in Houston. Photo via Getty Images

In Houston, $100,000 per year goes much farther than many other Texas cities. A new study by personal finance website GOBankingRates.com ranked Houston No. 7 on its list of the best cities for six-figure earners in the U.S.

The annual net pay after taxes for a six-figure earner in Houston comes out to $78,089, according to the study. When factoring in major expenses like rent, groceries, healthcare, utilities, transportation costs, and miscellaneous expenses, that adds up to $43,105.46 per year, which leaves just under $35,000 leftover. Houston's continuing inflation troubles surely aren't helping, either.

Here's how GOBankingRates breaks down Houston's expenses:

  • Annual rent: $19,215.67
  • Annual groceries: $5,594.64
  • Annual healthcare: $5,563.35
  • Annual utilities: $4,389.79
  • Annual transportation costs: $7,364.29
  • Annual miscellaneous costs: $977.72
Houston appears one spot lower than its No. 6-rank in a similar 2023 study by SmartAsset. That study said Houstonians' six-figure salary was reduced to $74,515 after taxes, but was technically worth $81,350 when adjusted for the cost of living.

Houston wasn't the only Texas city to earn a spot in the top 10 where a six-figure salary goes the farthest. Higher up on the list is El Paso (No. 2) and San Antonio (No. 3).

After taxes and annual expenses, six-figure earners in El Paso have $37,685 left over, which is over $2,700 more than what a Houstonian would have with the same salary. In San Antonio, residents making $100,000 per year average about $41,008 in annual expenses, which leaves $37,081 in their pockets after paying all the bills.

For the second year in a row, the U.S. city where a $100,000 salary goes the furthest is Memphis, Tennessee. Memphis residents have nearly $40,000 leftover after taxes and annual expenses on a $100,000 salary, the study says. Like Texas, Tennessee also doesn't impose an income tax on its residents.

The top 10 U.S. cities where a $100,000 salary goes the farthest are:

  • No. 1 – Memphis, Tennessee
  • No. 2 – El Paso, Texas
  • No. 3 – San Antonio, Texas
  • No. 4 – Tulsa, Oklahoma
  • No. 5 – Oklahoma City, Oklahoma
  • No. 6 – Wichita, Kansas
  • No. 7 – Houston
  • No. 8 – Tucson, Arizona
  • No. 9 – Jacksonville, Florida
  • No. 10 – Indianapolis, Indiana

In the study's analysis of the top 10 most expensive cities for six-figure earners, New York City took the crown as the city where residents are left "in the red" by the end of the year. Following close behind is San Francisco, California (No. 2); San Jose, California (No. 3); San Diego, California (No. 4); Boston, Massachusetts (No. 5); Oakland, California (No. 6); Los Angeles, California (No. 7); Washington, D.C. (No. 8); Miami, Florida (No. 9); and Long Beach, California (No. 10).

The report analyzed the average expense costs in 50 of the most populous American cities, and subtracted those costs from each city's annual net annual pay after taxes on a $100,000 salary. Rankings were determined based on the amount of annual income leftover. Data was pulled from the U.S. Census American Community Survey, the Bureau of Labor Statistics Consumer Expenditure Survey, the Zillow Observed Rental Index, and more.The report and its methodology can be found on gobankingrates.com.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston hospital names leading cancer scientist as new academic head

new hire

Houston Methodist Academic Institute has named cancer clinician and scientist Dr. Jenny Chang as its new executive vice president, president, CEO, and chief academic officer.

Chang was selected following a national search and will succeed Dr. H. Dirk Sostman, who will retire in February after 20 years of leadership. Chang is the director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She has been with Houston Methodist for 15 years.

Over the last five years, Chang has served as the institute’s chief clinical science officer and is credited with strengthening cancer clinical trials. Her work has focused on therapy-resistant cancer stem cells and their treatment, particularly relating to breast cancer.

Her work has generated more than $35 million in funding for Houston Methodist from organizations like the National Institutes of Health and the National Cancer Institute, according to the health care system. In 2021, Dr. Mary Neal and her husband Ron Neal, whom the cancer center is now named after, donated $25 million to support her and her team’s research on advanced cancer therapy.

In her new role, Chang will work to expand clinical and translational research and education across Houston Methodist in digital health, robotics and bioengineered therapeutics.

“Dr. Chang’s dedication to Houston Methodist is unparalleled,” Dr. Marc L. Boom, Houston Methodist president and CEO, said in a news release. “She is committed to our mission and to helping our patients, and her clinical expertise, research innovation and health care leadership make her the ideal choice for leading our academic mission into an exciting new chapter.”

Chang is a member of the American Association of Cancer Research (AACR) Stand Up to Cancer Scientific Advisory Council. She earned her medical degree from Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research. She earned her research doctorate from the University of London.

She is also a professor at Weill Cornell Medical School, which is affiliated with the Houston Methodist Academic Institute.

Texas A&M awarded $1.3M federal grant to develop clean energy tech from electronic waste

seeing green

Texas A&M University in College Station has received a nearly $1.3 million federal grant for development of clean energy technology.

The university will use the $1,280,553 grant from the U.S. Department of Energy to develop a cost-effective, sustainable method for extracting rare earth elements from electronic waste.

Rare earth elements (REEs) are a set of 17 metallic elements.

“REEs are essential components of more than 200 products, especially high-tech consumer products, such as cellular telephones, computer hard drives, electric and hybrid vehicles, and flat-screen monitors and televisions,” according to the Eos news website.

REEs also are found in defense equipment and technology such as electronic displays, guidance systems, lasers, and radar and sonar systems, says Eos.

The grant awarded to Texas A&M was among $17 million in DOE grants given to 14 projects that seek to accelerate innovation in the critical materials sector. The federal Energy Act of 2020 defines a critical material — such as aluminum, cobalt, copper, lithium, magnesium, nickel, and platinum — as a substance that faces a high risk of supply chain disruption and “serves an essential function” in the energy sector.

“DOE is helping reduce the nation’s dependence on foreign supply chains through innovative solutions that will tap domestic sources of the critical materials needed for next-generation technologies,” says U.S. Energy Secretary Jennifer Granholm. “These investments — part of our industrial strategy — will keep America’s growing manufacturing industry competitive while delivering economic benefits to communities nationwide.”

------

This article originally appeared on EnergyCapital.

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

View All Listings